Trial reportRespiratory research2018
Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.
Trial report in Respiratory research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy
Evaluation of the Efficacy of Different Nebulization Techniques in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients, Randomized, Single-blind, Clinical Trial
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Differentiating the start of an exacerbation from day-to-day variation in people with COPD: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Remote Patient Monitoring and Machine Learning in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Dual Systematic Literature Review and Narrative Synthesis.Journal of medical Internet research · 2024Pooled it
- An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial.International journal of chronic obstructive pulmonary disease · 2021Trial
- Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.Current allergy and asthma reports · 2026Review
- Excessive Short-acting Beta-agonists Prescriptions in COPD Treated with Triple Inhaler Therapy: A Possible Marker of Frequent Exacerbations. A Retrospective Cohort Study.Thoracic research and practice · 2026Article
- A Proposed Checklist for Optimizing COPD Patient Discharge Processes in Italian Internal Medicine Wards.International journal of chronic obstructive pulmonary disease · 2026Review
- Addressing Cardiopulmonary Risk in COPD: A Multidisciplinary Expert Opinion Framework for the United States Healthcare System.International journal of chronic obstructive pulmonary disease · 2026Review
- Clinical Provider Perspectives on Remote Spirometry and mHealth for COPD.Nursing reports (Pavia, Italy) · 2025Article
- Feasibility, quality and added value of unsupervised at-home spirometry in primary care.NPJ primary care respiratory medicine · 2025Article
- Pleural Effusions Requiring Thoracocentesis Are Associated With Baseline Lung Allograft Dysfunction and Mortality in Lung Transplant Recipients.Clinical transplantation · 2025Article
- Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan.Advances in therapy · 2024Article
- [Chronic obstructive pulmonary disease (COPD): eosinophilia and novel drug therapies].Innere Medizin (Heidelberg, Germany) · 2024Review
- Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review.Advances in therapy · 2024Review
- Mortality prevention as the centre of COPD management.ERJ open research · 2024Review
- Rate of severe exacerbations, healthcare resource utilisation and clinical outcomes in patients with COPD in low-income and middle-income countries: results from the EXACOS International Study.BMJ open respiratory research · 2024Article
- Effect on Physical Position of Peak Inspiratory Flow in Stable COPD: An Observational Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- The disruptive effects of COPD exacerbation-associated factors on epithelial repair responses.Frontiers in immunology · 2024Article
- Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Are There Significant Differences Between Hospitalized and Emergency Department Patients?International journal of chronic obstructive pulmonary disease · 2024Article
- The initial angle of the maximum expiratory flow-volume curve: a novel start-of-test criteria of spirometry in children.European journal of pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExacerbations of chronic obstructive pulmonary disease (COPD) are associated with loss of lung function and poor outcomes for patients. However, there are limited data on the time course of changes in forced expiratory volume in 1 s (FEV
methodsWISDOM was a multinational, randomized, double-blind, active-controlled, 52-week study in patients with severe-to-very severe COPD. Patients received triple therapy (long-acting muscarinic antagonist and long-acting β
resultsEight hundred and eighty-eight patients in the WISDOM study had a moderate/severe exacerbation after the complete ICS withdrawal visit; 360 of them contributed at least one FEV
conclusionsMean lung function starts to decline prior to the first reported symptoms of an exacerbation, and does not recover to pre-exacerbation levels 8 weeks after the event.
trial registrationWISDOM (ClinicalTrials.gov number, NCT00975195 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.